The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Administrative Unit aims to effectively generate and administer the policies, procedures, communications, and funds associated with CEGIR. The CEGIR Administrative Unit will be integral in coordinating decision-making and implementation to achieve the objectives of CEGIR. The CEGIR Administrative Unit will include the CEGIR Director (Principal Investigator), Administrative Director, and the CEGIR Internal CEGIR Steering Committee. The Internal CEGIR Steering Committee has strong patient advocacy group [PAG;e.g. American Partnership for Eosinophilic Disorders (APFED) and Campaign Urging Research for Eosinophilic Diseases (CURED)] and professional medical research group representation [e.g. International Eosinophil Society (lES) and The International Gastrointestinal Eosinophil Researchers (TIGER)]. Specific activities ofthe CEGIR Administrative Unit include but are not limited to the following: 1) generate and administer policies;2) administer and monitor funds;3) ensure proper research conduct by all sites, including patient enrollment and retention;4) review reports from each CEGIR program/component;5) communicate and report to the National Institutes of Health (NIH) and other regulatory bodies;6) disseminate findings, including publications;7) disseminate web-based information as per NIH guidelines and directives;8) foster integration and partnership with PAGs;9) report to the External Advisory Board (EAB) and review their recommendations;and 10) conduct regular teleconferences, webinars, and meetings.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cincinnati Children's Hospital Medical Center
United States
Zip Code
Mehta, Pooja; Sundaram, Shikha; Furuta, Glenn T et al. (2016) Propofol Use in Pediatric Patients With Food Allergy and Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr :
Molina-Infante, Javier; Bredenoord, Albert J; Cheng, Edaire et al. (2016) Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut 65:524-31
Imam, Tanbeena; Gupta, Sandeep K (2016) Topical glucocorticoid vs. diet therapy in eosinophilic esophagitis: the need for better treatment options. Expert Rev Clin Immunol 12:797-9
Kliewer, Kara L; Venter, Carina; Cassin, Alison M et al. (2016) Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet? J Allergy Clin Immunol 137:1011-4
Morris, David W; Stucke, Emily M; Martin, Lisa J et al. (2016) Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis. J Allergy Clin Immunol 138:915-918.e5
Watts, Abhishek; Alexander, Jeffrey A; Gupta, Sandeep K (2016) Eosinophilic esophagitis: search for noninvasive techniques for long-term monitoring. Gastrointest Endosc 83:307-8
Hill, David A; Spergel, Jonathan M (2016) The Immunologic Mechanisms of Eosinophilic Esophagitis. Curr Allergy Asthma Rep 16:9
Gonsalves, Nirmala; Furuta, Glenn T; Atkins, Dan (2016) Eosinophilic Gastrointestinal Disorders Affect More Than Just the Esophagus. J Pediatr Gastroenterol Nutr 62:1-2
Nguyen, Nathalie; Furuta, Glenn T; Masterson, Joanne C (2016) Deeper Than the Epithelium: Role of Matrix and Fibroblasts in Pediatric and Adult Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr 63:168-9
Rawson, Renee; Yang, Tom; Newbury, Robert O et al. (2016) TGF-β1-induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis. J Allergy Clin Immunol 138:791-800.e4

Showing the most recent 10 out of 37 publications